Tangier disease; High density lipoprotein deficiency, type 2; Tangier disease, variant; High density lipoprotein deficiency; Coronary heart disease in familial hypercholesterolema, protection aganist
Substrate In Vitro Evidence:
1. Free Cholesterol Efflux - Using J774 macrophages - Kellner-Weibel G, Atherosclerosis 2003: 235-243
2. Phospholipid efflux - Oram JF, Current Opinion in Lipidology 2002, 373-381
3. Interleukin 1-beta transport in Macrophages, but not monocytes from normal and TD patients- Xiaoqin Zhou et al, Biochemical and Biophysical Research Communications, 2002: 598-604
4. Apolipoprotein E secretion from monocyte-derived macrophages- Von Eckardstein A et al, FASEB, 2001: 1555-1561
Substrate In Vivo Evidence:
1. Atherogenesis, Tangier's Disease, Familial Hypoalphalipopreteinemia (FHA) - Singaraja RR et al, Ateriosclerosis Thrombosis and Vascular Biology 2003: 1322-1332
2. Apoptotic cell Engulfment by macrophages - Broccando C et al, Biochimica et Biophysica Acta, 1999: 395-404
3. ABCA1 modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice, Joyce CW et al, PNAS 2002: 407-412
4. Glyburide inhibits ApoE secretion - Von Eckardstein A et al, FASEB, 2001: 1555-1561
Tissue Distribution Evidence:
1. Macrophages
2. Liver
3. Lymph node
4. Adrenals
5. Uterus
6. Low in Brain and Lung
By Northern Blot
Reference: C. Broccardo et al, Biochimia et Biophysica Acta 1461 (1999) 395-404
Transmembrane prediction: Non-synonymous amino acid changes shown in red, indels (insertions and deletions) in blue, and synonymous changes in green. Exon(s) indicated by black outlines.
Copyright 2009, UCSF Pharmacogenetics of Membrane Transporters. All rights reserved.